Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Reimbursement News › Myriad Genetics BRCA Test to be Reimbursed in Japan

Myriad Genetics BRCA Test to be Reimbursed in Japan

Apr 06, 2020
|
staff reporter

NEW YORK – Myriad Genetics' BRACAnalysis Diagnostic System will be reimbursed in Japan as a test to identify whether individuals with hereditary breast and ovarian cancer syndrome have BRCA1/2 mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
23
Featured Webinar

Liquid Biopsy to Understand Resistance Mechanisms in Non-Small Cell Lung Cancer

Sponsored by
Inivata

In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment. 

What's Popular?

In Molecular Diagnostics

  1. Genetic Testing Challenges in Oncology: Surgeon Recommends Mastectomy for Woman With RAD50 Mutation

  2. Oncocyte DetermaRx Predicts Early Lung Cancer Outcomes Regardless of EGFR Status

    Premium

  3. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.